About Boston Biomedical
Boston Biomedical is a Healthcare company based in Boston (United States) founded in 2006, and was acquired by Sumitomo Dainippon Pharma in February 2012. It develops novel therapeutics for treatment of cancer. Boston Biomedical has raised $2 million across 2 funding rounds from investors including HHS and Sumitomo Dainippon Pharma. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Boston Biomedical is a privately held biotechnology company focusing on research and development of novel therapeutics to treat cancer. Beginning with initial focus on cancer stemcell pathways, company today has more than 20 clinical programs in pipeline. Two lead products at various phases of clinical trials for different types of cancer are Napabucasin and BB503. Other oncology programs include DSP-7888, an investigational agent approved by USFDA. Company got acquired by ds-pharma in 2012 for 200M USD upfront with milestone achievement being upto as high as 2.6B USD.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Website bostonbiomedical.com
- Social LinkedIn X Facebook
- Acquired by Sumitomo Dainippon Pharma (Feb 2012)
- Total Equity Funding$2M (USD)
in 2 rounds
- Latest Funding Round$2M (USD), Seed
Jun 2010
- InvestorsHHS
& 1 more
- Acquired bySumitomo Dainippon Pharma
(Feb 2012)
Funding Insights of Boston Biomedical
Boston Biomedical has successfully raised a total of $2M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2M
- Total Rounds 2
- Last Round Seed β $2M
- First Round $485,527
(Apr 2010)
- Investors Count 1
All 2 funding rounds of Boston Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2010 | $2M | Seed | β | β | β |
| Apr 2010 | $485,527 | Grant | β | β |
2 investors in total: 2 institutional.
Investors in Boston Biomedical
Boston Biomedical has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured. | 1897 | ds-pharma.com | Osaka, Japan |
Investor details for Boston Biomedical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Boston Biomedical
4 dated milestones of Boston Biomedical across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Boston Biomedical is founded.
- Funding First funding round of $486K.
- Funding Latest funding round, Seed, of $2.0M.
- Exit Acquired by Sumitomo Dainippon Pharma.
Competitors of Boston Biomedical
Boston Biomedical has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Boston Biomedical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Boston Biomedical
Websites that share an audience with Boston Biomedical (bostonbiomedical.com).
Websites whose visitors overlap most with Boston Biomedical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| chronixbiomedical.com | 100% | View details | |||
dspbio.co.jp | dspbio.co.jp | 99% | β | ||
| ds-pharma.com | 97% | View details | |||
| gene-lab.com | 96% | View details | |||
| lupinpharmaceuticals.com | 96% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 8 similar websites and full traffic analytics for Boston Biomedical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Boston Biomedical (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Boston Biomedical
Complete news archive for Boston Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boston Biomedical
Boston Biomedical was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Boston Biomedical is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Boston Biomedical is a funded company, having raised a total of $2M across 2 funding rounds to date. The company's 1st funding round was a Grant of $485.53K, raised on Apr 2010.
Boston Biomedical is a privately held biotechnology company focusing on research and development of novel therapeutics to treat cancer. Beginning with initial focus on cancer stemcell pathways, company today has more than 20 clinical programs in pipeline. Two lead products at various phases of clinical trials for different types of cancer are Napabucasin and BB503. Other oncology programs include DSP-7888, an investigational agent approved by USFDA. Company got acquired by ds-pharma in 2012 for 200M USD upfront with milestone achievement being upto as high as 2.6B USD.
Boston Biomedical's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Boston Biomedical has 2 investors. Key investors include HHS, and Sumitomo Dainippon Pharma.
Yes. Boston Biomedical was acquired by Sumitomo Dainippon Pharma in February 2012.

